Literature DB >> 32282769

Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesions.

Teppei Yoshioka1, Minoru Shigekawa, Kenji Ikezawa, Takeshi Tamura, Katsuhiko Sato, Makiko Urabe, Hironari Sueyoshi, Takuo Yamai, Takahiro Suda, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara.   

Abstract

OBJECTIVES: Pancreatic cystic lesions (PCLs) are a risk factor for pancreatic cancer (PC). Which PCLs should be surveilled and necessity of long-term observation are still controversial.
METHODS: From January 2000 to March 2016, we enrolled 1137 patients with PCLs observed for 1 year. We defined PCLs with cyst size of greater than 30 mm, main pancreatic duct (MPD) of greater than 5 mm or mural nodule as high-risk group, and others as low-risk group (LRG). Kaplan-Meier method and Cox proportional hazard model were applied to assess incidence and risk factors of PC.
RESULTS: In 107 high-risk group and 1030 LRG patients, mean observation period was 4.3 years and 5.0 years, respectively, and 5-year PC incidence was 12.0% and 2.8%, respectively. In LRG, MPD of greater than 3 mm, diabetes mellitus, and presumed branch-duct intraductal papillary mucinous neoplasia (BD-IPMN), defined as PCLs fulfilling any of multilocular formation, multiplicity, or MPD communication, were independent risk factors for PC. In 450 LRG observed for 5 years, 10-year PC incidence was higher in PCLs with our identified risk factors. There was no PC occurrence in PCLs not presumed BD-IPMN after 5-year observation.
CONCLUSIONS: Continuous surveillance is needed after 5-year observation, especially in LRG with our identified risk factors. For discontinuing surveillance, PCLs not presumed BD-IPMN at fifth year could be candidates.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32282769     DOI: 10.1097/MPA.0000000000001521

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  5 in total

1.  Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals.

Authors:  Junko Fukuda; Kenji Ikezawa; Miho Nakao; Suetsumi Okagaki; Reiko Ashida; Tatsuya Ioka; Ryoji Takada; Takuo Yamai; Nobuyasu Fukutake; Hiroyuki Uehara; Shigenori Nagata; Hidenori Takahashi; Takahiro Tabuchi; Sachiko Tanaka; Kazuyoshi Ohkawa; Kazuhiro Katayama
Journal:  Cancers (Basel)       Date:  2021-01-28       Impact factor: 6.639

2.  Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer.

Authors:  Kenji Ikezawa; Tomoya Ekawa; Shinichiro Hasegawa; Yugo Kai; Ryoji Takada; Takuo Yamai; Nobuyasu Fukutake; Hisataka Ogawa; Takashi Akazawa; Yu Mizote; Kumiko Tatsumi; Shigenori Nagata; Kei Asukai; Hidenori Takahashi; Kazuyoshi Ohkawa; Hideaki Tahara
Journal:  Endosc Int Open       Date:  2022-01-11

3.  International external validation of a stratification tool to identify branch-duct intraductal papillary mucinous neoplasms at lowest risk of progression.

Authors:  Kasper A Overbeek; Nikki van Leeuwen; Matteo Tacelli; Muhammad S Anwar; Muhammad N Yousaf; Ankit Chhoda; Paolo Giorgio Arcidiacono; Tamas A Gonda; Michael B Wallace; Gabriele Capurso; James J Farrell; Djuna L Cahen; Marco J Bruno
Journal:  United European Gastroenterol J       Date:  2022-02-24       Impact factor: 4.623

4.  Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer.

Authors:  Kenji Ikezawa; Ryosuke Kiyota; Ryoji Takada; Kazuma Daiku; Shingo Maeda; Toshihiro Imai; Yutaro Abe; Yugo Kai; Takuo Yamai; Nobuyasu Fukutake; Tasuku Nakabori; Reiko Ashida; Hiroyuki Uehara; Takahiro Tabuchi; Kazuhiro Katayama; Kazuyoshi Ohkawa
Journal:  JGH Open       Date:  2021-05-10

5.  Pancreatic mesothelial cyst.

Authors:  Charbel Chater; Joseph Obeid Obeid; Seba Mhanna
Journal:  BMJ Case Rep       Date:  2020-10-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.